Prior to the establishment of the enrichment workflow, the immunofluorescence staining of markers, whose expression is required for the CTC detection within the FDA-approved CellSearch ® [52] , was validated on fixed MCF-7 cells and on leukocytes. At first, the cell count was determined by adding 10 µL each cell suspension to 10 µL of trypan blue (Sigma-Aldrich). Then, 10 µL of mixtures was added into two different sampling area of a Neubauer counting chamber (Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, Germany) . Afterwards, an amount of 50000 cells/400 µL PBS per each suspension, was spun onto SuperFrost slides (R. Langenbrinck, Emmendligen, Germany) through a ROTOFIX 32 A centrifuge (600 g, 3 min; Hettich GmbH & Co.KG, Tuttlingen, Germany). Then, the supernatant was removed by aspiration and cytospins were left to dry overnight at RT. Afterwards, slides were stored at-20 °C.
Immunofluorescence
To validate the staining mastermix targeting nuclei, EpCAM, cytokeratins and CD45 altogether, immunostaining of fixed MCF-7 and leukocytes spun onto glass slides, was performed. At first, cytospins were washed with PBS and then incubated with 0.1% Triton X-100 (Sigma Aldrich) for 10 min, to permeabilize cell membranes. Afterwards, cells were incubated 1 h, at RT, dark, with the staining mastermix including (DAPI; Roche Diagnostics GmbH, Heilingenhaus, Germany), cytokeratins (clones C11/AE1/AE3 [12, 13] , TRITC conjugate; Aczon Srl, Monte San Pietro BO, Italy), EpCAM (clone VU1D9 [13] , Alexa Fluor ® 488 conjugated; Cell Signaling Technology Inc., Danvers, MA, USA) and CD45 (clone 35-ZS [13] , Alexa Fluor ® 647 conjugated; Santa Cruz Biotechnology Inc., Dallas, TX, USA), diluted in DAKO Antibody diluent (Agilent, Santa Clara, CA, USA). Cells were, then, washed twice with PBS. At the end, slides were mounted with the DAKO (Agilent) mounting medium, coverslips were applied and stored at 4 °C until imaging with the CellCelector™.
Spiking Experiments
Prior processing patients′ blood samples, the method was tested on MCF-7 cells. At first, the tumor cell enrichment though Parsortix™ system (ANGLE plc, Guildford, UK)-the novel component of our workflow-was determined through three independent spiking experiments. After processing through CellSearch ® system [27] , three blood samples of healthy donors were spiked with a defined amount of fixed and pre-labeled MCF-7. Then, spiked samples were processed through Parsortix™ system. Capturing and harvesting rates were assessed by fluorescence imaging via CellCelector™ of both cassettes and collected cell suspension respectively.
Further spiking experiments were performed to establish the staining of tumor cells captured within Parsortix™ cassettes. Fixed MCF7 cells were spiked into healthy donor blood samples after processing within the CellSearch ® system. Tumor cells which were captured inside the Parsortix™ cassette were permeabilized with 0.1% Triton X-100 for 10 min, washed with PBS and then incubated with the above reported antibodies/DAPI staining mastermix. Afterwards, stained cells were washed with PBS, harvested out of the system and the effective staining was assessed via immunofluorescence microscopy (CellCelector™). T1c  N0  M0  2  15  neg  0  46  XLII  75  neg  pos  pos  lobular  T2  N0  M0  2  131  pos  3  47  XLIII  67  *  pos  pos  *  T2  N1  M0  2  500  neg  0  48 XLIV 54 neg *** pos *** pos *** *  T1  N0  M0  2  115  neg  0  49  XLV  65  neg  pos  pos  ductal  T1c  N1  M0  3  59  neg  15  50  XLVI  48  neg  pos  pos  ductal  T1c  N0  M0  2  16  pos  8  51  XLVI (2)  48  neg  pos  pos  ductal  T1a  N0  M0  2  201  pos  0  52  XLVII  51  neg  pos  pos  ductal  T4b  N3a  M0  3  100 neg 3 * Unknown; ** CTC count could not be determined; *** receptor status determined on the DCIS; **** M status of primary tumour at the time of diagnosis. #: amount of processed blood samples.
